Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing growth in its customer base, particularly in the OBL and hospital settings, which is positively impacting its average selling prices (ASP) and contributing to overall revenue enhancement. The company is demonstrating a significant improvement in gross margins, currently reported at 52.5%, driven by manufacturing initiatives and a favorable shift in revenue mix towards higher Med-Tech revenues. Management's confidence in continued growth is supported by the acquisition of new customers, increased utilization in existing accounts, and successful price increases across its product offerings.

Bears say

AngioDynamics Inc. faces potential financial pressures, as management anticipates $4 million to $6 million in tariff headwinds, which could negatively impact profitability. In addition, expectations for inventory costs in the second half of fiscal year 2026 are facing increased pressure from rising raw material prices. Although the sales of NanoKnife disposables exceeded projections, reliance on capital sales raises concerns about future demand sustainability in the disposable segment.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.